We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adicet Bio, Inc. is one of 1187 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 31.7% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ACET has gained about 18.8% so far this year. Meanwhile, the Medical sector has returned an average of -16.5% on a year-to-date basis. This means that Adicet Bio, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is RxSight, Inc. (RXST - Free Report) . The stock has returned 20.4% year-to-date.
In RxSight, Inc.'s case, the consensus EPS estimate for the current year increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 562 individual stocks and currently sits at #62 in the Zacks Industry Rank. Stocks in this group have lost about 17.4% so far this year, so ACET is performing better this group in terms of year-to-date returns.
RxSight, Inc. however, belongs to the Medical - Instruments industry. Currently, this 103-stock industry is ranked #92. The industry has moved -29.9% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and RxSight, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adicet Bio, Inc. is one of 1187 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 31.7% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ACET has gained about 18.8% so far this year. Meanwhile, the Medical sector has returned an average of -16.5% on a year-to-date basis. This means that Adicet Bio, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is RxSight, Inc. (RXST - Free Report) . The stock has returned 20.4% year-to-date.
In RxSight, Inc.'s case, the consensus EPS estimate for the current year increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 562 individual stocks and currently sits at #62 in the Zacks Industry Rank. Stocks in this group have lost about 17.4% so far this year, so ACET is performing better this group in terms of year-to-date returns.
RxSight, Inc. however, belongs to the Medical - Instruments industry. Currently, this 103-stock industry is ranked #92. The industry has moved -29.9% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and RxSight, Inc. as they could maintain their solid performance.